乳腺X线筛查导致的必然过度诊断:美国女性的直接估计
本研究利用人类死亡率数据库的全因死亡率、SEER的乳腺癌发病与死亡率以及筛查试验的领先时间数据,估计美国乳腺X线筛查女性中导管原位癌、浸润性乳腺癌及全部乳腺癌的必然过度诊断率。结果发现必然过度诊断率随筛查年龄增长而迅速升高,40岁时低于1%,80岁时分别为30%、21%和22.5%;美国筛查人群中总体必然过度诊断率DCIS为9%、浸润性癌和全部乳腺癌均约7%。
要点
- 必然过度诊断率随筛查年龄增长迅速升高,80岁时DCIS达30%、浸润性癌21%、全部乳腺癌22.5%。
- 美国筛查人群中必然过度诊断率DCIS为9%,浸润性癌和全部乳腺癌均约7%。
- 40-49岁女性筛查对必然过度诊断率贡献很小:DCIS为0.15%,浸润性癌和全部乳腺癌均低于0.1%。
核心结论
- 必然过度诊断率随筛查年龄增长而迅速升高;美国乳腺X线筛查人群中必然过度诊断率DCIS为9%,浸润性癌和全部乳腺癌均约7%,40-49岁女性筛查的贡献很小。
研究设计与样本
- 利用人类死亡率数据库年龄别全因死亡率、SEER年龄别乳腺癌发病与死亡率以及乳腺癌筛查试验的领先时间均值和分布,估计美国乳腺X线筛查女性的必然过度诊断率。
诊断标准与关键数值
- 必然过度诊断定义为筛查发现的乳腺癌女性在该癌临床显现前死于其他原因的比例。
- 40岁时必然过度诊断率低于1%;80岁时DCIS为30%、浸润性癌为21%、全部乳腺癌为22.5%。
- 美国筛查人群中必然过度诊断率DCIS为9%,浸润性癌和全部乳腺癌均约7%。
- 40-49岁女性筛查增加必然过度诊断率DCIS为0.15%,浸润性癌和全部乳腺癌均低于0.1%。
局限性
- 原文未报告局限性
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
英文原文(摘要)· 点击展开
Purpose To determine obligate overdiagnosis rates, defined as the percentage of women diagnosed with screen-detected breast cancer who die of causes other than breast cancer prior to clinical presentation of that cancer, for ductal carcinoma in situ (DCIS), invasive breast cancer, and all breast cancers. Materials and Methods Age-specific all-cause mortality rates from the Human Mortality Database, age-specific breast cancer incidence and mortality rates from Surveillance, Epidemiology, and End Results data, and estimates of mean lead times and lead time distributions from breast cancer screening trials are used to estimate obligate (or type 1) overdiagnosis rates for DCIS, invasive breast cancer, and all breast cancers (DCIS plus invasive) for U.S. women undergoing screening mammography. Mortality rates by age are used to estimate the number of women who die of causes other than breast cancer during the lead time afforded by screening mammography. Resulting age-dependent overdiagnosis rates, along with screen-detected breast cancer incidence by age, are used to estimate type 1 overdiagnosis rates for the U.S. screening population. Results Obligate overdiagnosis rates depend strongly on the age at which a woman is screened, ranging from less than 1% at age 40 years to 30%, 21%, and 22.5% at age 80 years for DCIS, invasive breast cancer, and all breast cancers, respectively. Type 1 overdiagnosis rates among screened women in the United States are estimated to be 9% for DCIS and approximately 7% for both invasive breast cancer and all breast cancers. Screening of women ages 40-49 years (or premenopausal women, as determined from patient history, starting at age 40 years) adds little to obligate overdiagnosis rates (0.15% for DCIS and less than 0.1% for invasive breast cancer and all breast cancers). Conclusion Type 1 overdiagnosis rates increase rapidly with age at screening. Obligate overdiagnosis occurs in 9% of DCIS and approximately 7% of both invasive breast cancer and all breast cancers in the U.S. mammographic screening population, with screening of women ages 40-49 years (or premenopausal women starting at age 40 years) making a negligible contribution of 0.15% to obligate overdiagnosis of DCIS and a contribution of less than 0.1% to the obligate overdiagnosis rates of invasive breast cancer and all breast cancers. © RSNA, 2017 Online supplemental material is available for this article.
引用
- Hendrick RE. Obligate Overdiagnosis Due to Mammographic Screening: A Direct Estimate for U.S. Women. Radiology. 2017. PMID: 29267146. doi:10.1148/radiol.2017171622
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。